Phase 4 N=108 Antibiotic Resistance In Eye Surgeries
Antibiotic Resistance · Ocular Surface Microbiome · Gut Resistome
Primary: Antimicrobial Resistance (AMR) of Conjunctiva at 1 Week — 0; 0; 0 reads per million reads — p=1
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=33 Enhanced, Personalized and Integrated Care for Infection Management at the Point-Of-Care
Antibiotic Resistant Infection · Infection
Primary: Percentage of Appropriate Antimicrobial Prescriptions Recommended — 90 percentage of prescriptions appropriate
Phase 4 N=248 Antibiotic Resistance and Microbiome in Children Aged 6-59 Months in Nouna, Burkina Faso
Child Development
Primary: Simpson's Index of Diversity (Alpha Diversity) in Intestinal Microbiome — 10.2; 8.8; 9.7; 9.6 Index score
Phase 2 N=19 Topical Antibiotics in Chronic Rhinosinusitis
Chronic Rhinosinusitis (Diagnosis)
Primary: Subjects Who Developed Antibiotic Resistance Organisms — 0; 0; 1; 0 Participants
N/A N=2,140 Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance
Methicillin-resistant Staphylococcus Aureus
Primary: Time to MRSA Infection — 67; 98; 68; 98 Participants — p=0.026
Phase 1 N=7 Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization
Antibiotic Resistant Strain
Primary: Number of Participants With Adverse Events (NIH Grade ≥2) at Day 7 After Randomization — 4; 0 Participants
Phase 3 N=2,265 Strategies Using Off-Patent Antibiotics for Methicillin Resistant S. Aureus "STOP MRSA"
Staphylococcal Infection
Primary: Number of Participants With Clinical Cure as of the Test-of-Cure (TOC) Visit in the Per Protocol Population — 457; 487; 182; 187 participants
N/A N=120 Bacterial Resistance in Patients Receiving Post-Intravitreal Injection Antibiotics
Bacterial Resistance
Primary: Number of Participants With Resistance of Ocular Flora to Commonly Used Post-injection Prophylactic Antibiotics — 10; 6 Participants
N/A N=110 Restricted Reporting for Positive Urine Cultures
Bacteriuria · Urinary Tract Infection
Primary: The Number of Patients Receiving Appropriate Treatment — 44; 29 Participants
N/A N=4 Improving Antimicrobial-Prescribing in Emergency Departments
Anti-Bacterial Agents · Respiratory Tract Infections
Primary: Percentage of Patient-visits Prescribed an Antimicrobial at Their ED Visit — 21.2; 20.9; 19.1; 21.6 percentage of visits prescribed an abx — p=0.35
Phase 4 N=103 The Use of Probiotics to Evaluate Colonization With Antimicrobial Resistant Bacteria
Infectious Disease of Digestive Tract
Primary: Number of Participants With Combination of Gastrointestinal Tract Colonization With Multi-drug Resistant Gram-negative Bacteria, C. Difficile and VRE — 8; 8 Participants
Phase 4 N=924 Clarithromycin Resistant Tailored Therapy
Peptic Ulcer · Helicobacter Pylori Infection
Primary: Helicobacter Pylori Eradication Rate — 75.9; 91.2; 79.1 percentage of participants
N/A N=31 Trial of Antibiotic Treatment for Skin Abscess in Patients at Risk for Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Abscess
Primary: Clinical Improvement at 7 Days After Incision and Drainage — 10; 14 participants
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
N/A N=100 Modified Reporting of Positive Urine Cultures Collected From Long Term Care
Urinary Tract Infections · Asymptomatic Bacteriuria
Primary: Proportion of Asymptomatic Bacteriuria Treated With Antibiotics and Urinary Tract Infection Treated With Antibiotics — 31; 25 Participants
N/A N=248 Use of Behavioral Economics to Improve Treatment of Acute Respiratory Infections (Main Study)
Acute Respiratory Infections (ARIs)
Primary: Inappropriate Antibiotic Prescribing Rate for Qualifying Acute Respiratory Infection Diagnoses — 0.20; 0.19; 0.08; 0.09 proportion of visits
Phase 1 N=1 FMT for Multidrug Resistant Organism Reversal
Infection With Multi-drug Resistant Organisms
Primary: Safety of FMT in Patients With Recurrent MDRO Infections (Incidence and Severity of Solicited and Serious Adverse Events) — 0; 1 Participants
N/A N=463 A Novel Approach to Methicillin-resistant Staphylococcus Aureus (MRSA) Screening of Colonized Patients
MRSA Colonization
Primary: Number of Subjects With Single Negative Polymerase Chain Reaction (PCR) Result and 3 Negative Culture Assays — 96.6 percentage of participants
Phase 4 N=42 Trial Comparing Ceftriaxone Plus Azithromycin Versus Ceftriaxone for the Treatment of Gonorrhea
Neisseria Gonorrhoeae
Primary: Macrolide Resistance Determinants — 110.3; 167.53 normalized determinants/million reads — p=0.1026
Phase 3 N=588 The Evaluation of a Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB
MDR-TB
Primary: STREAM Stage 2 Primary Outcome Measure (the Proportion of Patients With a Favourable Outcome at Week 76) — 0; 133; 162; 122 Participants
Phase 3 N=32 Aztreonam for Pharyngeal Gonorrhea
Gonorrhea of Pharynx · Gonorrhea
Primary: Treatment Efficacy of Pharyngeal Gonorrhea as Defined as the Proportion of Study Participants With Positive Pharyngeal Gonorrhea Culture at of Enrollment Whose Test of…
Phase 4 N=30 Evaluate Effectiveness of Epiduo® Gel in Reducing Antibiotic Sensitive & Resistant Strains of Propionibacterium (P)Acnes
P Acnes Colonization
Primary: Change From Baseline in Quantitative Bacteriology Measurements at Week 4 — -1.6 log10 CFU/cm2
N/A N=203 Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections
Complicated Intra-Abdominal Infection
Primary: Duration of Hospitalization — 14.1 Days
N/A N=51 Comparison of Two Rescue Therapies for Helicobacter Pylori Infection
Helicobacter Pylori Infection
Primary: Number of Participants in Which H. Pylori Was Eradicated — 13; 21 participants
Phase 3 N=464 Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
Pneumonia · Blood Stream Infection
Primary: Mortality — 92; 78; 122; 133 Participants — p=0.21
Phase 4 N=510 Antibiotic Prophylaxis for Transrectal Prostate Biopsy
Infection
Primary: Number of Participants With Post-biopsy Infection. — 6; 3 participants — p=<0.05
N/A N=262 Acinetobacter Baumannii-related Osteomyelitis: Clinical and Epidemiological Characterization
Osteomyelitis
Primary: Description of the Clinical and Epidemiological Profile of Patients With Infection — 92; 26; 25; 21 Participants
Phase 4 N=18 Stop Community MRSA Colonization Among Patients
MRSA
Primary: Number of Participants With Recurrent Methicillin-resistant Staphylococcus Aureus (MRSA) Colonization — 2; 3 Participants
Phase 4 N=53 Retapamulin for Reducing MRSA Nasal Carriage
Methicillin-Resistant Staphylococcus Aureus
Primary: Proportion of Participants With MRSA Clearance — 8; 4 Participants — p=0.320
N/A N=219 The Efficacy of the Tailored Therapy Based on Antimicrobial Susceptibility for 2nd Eradication of H. Pylori
Helicobacter Infection
Primary: Number of Participants in Each Arm/Group With Successful H. Pylori Eradication — 67; 63; 36 participants